CRIS Current Research Information System

ANDRINI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.394
NA - Nord America 1.232
EU - Europa 821
AF - Africa 98
Continente sconosciuto - Info sul continente non disponibili 97
SA - Sud America 90
OC - Oceania 6
Totale 4.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.176
CN - Cina 631
VN - Vietnam 607
SG - Singapore 539
IT - Italia 366
HK - Hong Kong 165
BD - Bangladesh 149
KR - Corea 105
DE - Germania 80
NL - Olanda 69
BR - Brasile 68
IN - India 65
SE - Svezia 56
GB - Regno Unito 48
FI - Finlandia 35
CA - Canada 33
IE - Irlanda 33
JP - Giappone 33
CI - Costa d'Avorio 31
FR - Francia 31
CH - Svizzera 24
RU - Federazione Russa 22
TG - Togo 21
ID - Indonesia 14
JO - Giordania 14
TH - Thailandia 14
ZA - Sudafrica 14
SC - Seychelles 13
PH - Filippine 12
AT - Austria 11
BG - Bulgaria 10
MX - Messico 10
TW - Taiwan 10
TR - Turchia 9
IQ - Iraq 7
PL - Polonia 7
AU - Australia 6
AR - Argentina 5
MA - Marocco 5
CL - Cile 4
EC - Ecuador 4
JM - Giamaica 4
LT - Lituania 4
EG - Egitto 3
ES - Italia 3
GR - Grecia 3
HU - Ungheria 3
LB - Libano 3
NG - Nigeria 3
PK - Pakistan 3
SA - Arabia Saudita 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CO - Colombia 2
CR - Costa Rica 2
DZ - Algeria 2
HR - Croazia 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PY - Paraguay 2
TN - Tunisia 2
VE - Venezuela 2
AL - Albania 1
BB - Barbados 1
BE - Belgio 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GF - Guiana Francese 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
MT - Malta 1
NI - Nicaragua 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
Totale 4.641
Salva come PNG Salva come JPEG
Città #
Singapore 388
Hefei 217
Ashburn 202
San Jose 178
Ho Chi Minh City 170
Hong Kong 152
Hanoi 138
Seoul 99
Santa Clara 90
Bologna 78
Beijing 58
Council Bluffs 55
Boardman 41
Los Angeles 38
New York 36
Chandler 34
Dublin 33
Abidjan 31
Milan 31
Buffalo 28
Tokyo 26
Helsinki 25
Dong Ket 24
Bern 22
Fairfield 22
Dallas 21
Lomé 21
Bengaluru 19
Shanghai 19
Vicenza 19
Biên Hòa 18
Da Nang 18
Frankfurt am Main 17
Haiphong 17
Lauterbourg 17
São Paulo 17
Munich 16
Chicago 15
Amman 13
Southend 13
Turin 13
Houston 12
Hyderabad 11
Montreal 11
Rome 11
Amsterdam 10
Guangzhou 10
Johannesburg 10
Phoenix 10
Sofia 10
Nuremberg 9
Princeton 9
Quận Bình Thạnh 9
Redondo Beach 9
Tongling 9
Brooklyn 8
Falkenstein 8
Hải Dương 8
London 8
Seattle 8
Woodbridge 8
Wuhan 8
Can Tho 7
Jakarta 7
Lappeenranta 7
Mexico City 7
Modena 7
Newark 7
Tianjin 7
Bến Tre 6
Ha Long 6
Hangzhou 6
Rimini 6
Thái Bình 6
Toronto 6
Vienna 6
Charlotte 5
Düsseldorf 5
Naples 5
Orem 5
Palermo 5
Shenzhen 5
Wilmington 5
Bangkok 4
Bensalem 4
Bình Phước 4
Denver 4
Florence 4
Istanbul 4
Mumbai 4
Ninh Bình 4
Poplar 4
Redmond 4
San Francisco 4
Shijiazhuang 4
Thu Dau Mot 4
Warsaw 4
Xi'an 4
Atlanta 3
Baghdad 3
Totale 2.877
Salva come PNG Salva come JPEG
Nome #
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 237
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 236
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 204
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 196
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 188
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 185
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 177
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 176
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 174
Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms 174
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 170
Bone targeting agents in patients with metastatic prostate cancer: State of the art 169
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 166
An Update on Appendiceal Neuroendocrine Tumors 161
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 160
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 150
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 136
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis 123
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 119
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges 114
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC 103
β1600 Q.Clear Digital Reconstruction of [68Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients 98
Baseline neuronal antibodies in patients with small cell lung cancer are not necessarily associated with post-immune checkpoint inhibitors neurotoxicities 95
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 91
Non-small-cell lung cancer: how to manage RET-positive disease 84
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 81
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature 81
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 75
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids 73
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm 70
Safety and cost-effectiveness of immediate right hemicolectomy versus active surveillance for well-differentiated appendiceal neuroendocrine tumors 1-2 cm in size: a Markov decision analysis 67
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 62
Determinants of incidence trends in pancreatic neuroendocrine neoplasms 60
ARTEMIS: a pilot study comparing AI-based and expert therapeutic decisions in simulated clinical cases of neuroendocrine neoplasms 59
Multifocal paraneoplastic encephalitis associated with anti-GABA-B and anti-Hu antibodies manifesting with status epilepticus and epilepsia partialis continua: Expanding the clinical-radiological spectrum 56
Antibody–drug conjugates for lung cancer in the era of personalized oncology 55
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 45
Updates on Pulmonary Neuroendocrine Carcinoids: Progress and Perspectives 34
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer 34
Totale 4.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022110 0 0 2 4 8 3 3 19 10 6 40 15
2022/2023346 12 28 8 13 15 25 30 32 73 25 34 51
2023/2024158 9 17 6 12 9 35 13 19 6 16 9 7
2024/2025939 49 56 76 64 119 54 61 44 25 82 86 223
2025/20262.896 269 396 190 189 203 102 339 115 493 217 215 168
2026/2027176 76 100 0 0 0 0 0 0 0 0 0 0
Totale 4.738